key: cord-0855525-eoiimmen
authors: Jacobs, Jeffrey P.; Falasa, Matheus; Machuca, Tiago N.
title: COMMENTARY: Extracorporeal Membrane Oxygenation for Patients with Refractory COVID-19: What do We Know and What do We Need to Learn
date: 2020-12-03
journal: J Thorac Cardiovasc Surg
DOI: 10.1016/j.jtcvs.2020.11.128
sha: f010c69dcb295d1723295867c2f6c6b0c1115a94
doc_id: 855525
cord_uid: eoiimmen

nan

Shih, DiMaio, and colleagues are to be congratulated for their thoughtful analysis of "37 patients admitted with severe acute respiratory distress syndrome associated with COVID-19" who "were initiated on venovenous extracorporeal membrane oxygenation 0(VV ECMO) support at one of four ECMO referral hospitals within a large healthcare system. Initiation of ECMO occurred on median day 11.5 following admission, and, of the successfully decannulated patients, median time on ECMO was 17 days. Survival to discharge from ECMO center has occurred in 21/37 patients (56.8%)" [1] . These findings are important, and the authors and their team have made an extremely important contribution in these challenging times.

All of us have had our very existence impacted by the COVID-19 pandemic; indeed, life as we know it has changed dramatically and stunningly and rapidly and globally. The evolution of the treatment of patients with COVID-19 is unlike any event ever seen in medicine. As of November 19, 2020, 56,754,669 patients around the world have been diagnosed with COVID-J o u r n a l P r e -p r o o f 19, with 1,357,641 associated deaths to date (2.39% mortality worldwide) [2] . Meanwhile, in the United States of America, as of November 19, 2020, 11,689,545 patients have been diagnosed with confirmed COVID-19, with 252,290 associated deaths to date (2.16% mortality in the USA) [2] . Most deaths in patients with COVID-19 are due to severe respiratory failure, with a smaller group succumbing to combined pulmonary and cardiac failure. Several recent publications have documented that ECMO facilitates salvage and survival of select critically ill patients with COVID-19 [1, 3, 4, 5] . Early data from Wuhan, China reported an alarmingly high rate of mortality of 83% (5 out of 6) in COVID-19 patients supported with ECMO [6, 7] ; however, more recent data reveal improved survival of COVID-19 patients supported with ECMO [1, 3, 4, 5] . Both individual institutional reports [4] , as well as recent reports from multi-institutional registries [5] , have demonstrated promising results and important salvage of critically ill patients. patients with COVID-19 supported with ECMO at 20 hospitals [9] .

Ample evidence exists that ECMO facilitates salvage and survival of select critically ill patients with COVID-19. As of November 19, 2020, the Extracorporeal Life Support Organization (ELSO) COVID-19 Registry Dashboard includes 3344 patients worldwide with suspected or confirmed COVID-19 supported with ECMO and 3330 patients with confirmed COVID-19 supported with ECMO [10] . Of these patients, 2505 patients with confirmed COVID-19 had ECMO initiated at least 90 days prior to November 19, 2020, and these patients have an in-hospital mortality of 44%. Nevertheless, it is a fact that much remains to be learned about the treatment of patients with COVID-19 and the role of ECMO in this treatment.

Clinical guidelines for the management of patients with COVID-19 have been released by the World Health Organization (WHO) [11] and the Centers for Disease Control and Prevention (CDC) of the United States [12] . The Extracorporeal Life Support Organization (ELSO) [13] and The American Society for Artificial Internal Organs (ASAIO) [14] have also both published guidelines regarding the role of ECMO in treating patients with COVID-19.

Nevertheless, the role of ECMO in the management of these challenging patients remains promising but unclear. Areas that require ongoing investigation include (1) and (3) the type of ECMO support in these patients (e.g. anticoagulation strategy, cannulation strategy, type of circuit, type of oxygenator, and type of pump).

Much remains to be learned about the treatment of COVID and the role of ECMO in these challenging patients. It is clear that ECMO offers an important therapeutic option for a subset of critically ill patients with COVID-19. Recently, ECMO has also been used as a bridge to lung transplantation in some patients with COVID-19. Shih, DiMaio, and colleagues have provided important data demonstrating how cardiothoracic surgeons can help meet the challenges of the COVID-19 pandemic. As the treatment options for COVID-19 mature and evolve, cardiothoracic surgeons will continue to contribute.

J o u r n a l P r e -p r o o f

Venovenous Extracorporeal Membrane Oxygenation for Patients with Refractory COVID-19: Multicenter Experience of Referral Hospitals in a Large Healthcare System

Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering

Extracorporeal Membrane Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise in Coronavirus Disease 2019: Experience with 32 Patients

Extracorporeal Membrane Oxygenation Support in Severe COVID-19

Extracorporeal Life Support Organization. Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life

Epub ahead of print

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

COVID-19, ECMO, and lymphopenia: a word of caution

Experience with 100 patients with COVID-19 and Severe Pulmonary Compromise treated with Extracorporeal Membrane Oxygenation

Live Program cancelled secondary to COVID-19 Pandemic

Abstract Number: 925242. Analysis of 153 consecutive patients with COVID-19 and Severe Pulmonary Compromise treated with Extracorporeal Membrane Oxygenation (ECMO): Outcomes and Trends Over Time. Accepted for presentation as an oral livestream presentation at The Society of Thoracic Surgeons 2021 Annual Scientific Meeting, which will be held virtually

Full COVID-19 Registry Dashboard

Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected

Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19)

Initial ELSO guidance document: ECMO for COVID-19 patients with severe cardiopulmonary failure

Advanced pulmonary and cardiac support of